KR101313660B1 - Therapeutic effects cream for anti-atopic - Google Patents

Abstract

PURPOSE: An anti-atopic cream is provided to lower IgE in blood and to suppress discharge of histamine generated in mast cells, thereby treating atopic dermatitis. CONSTITUTION: An anti-atopic cream contains: a first ingredient including Houttuynia cordata, Acorus gramineus, Ledebouriella seseloides, Astragalus membranaceus BUNGE, loquat leaves, Sophora flavescens Solander ex Aiton, Saururus chinensis, Phellodendri cortex, Arisaema amurense Maximowicz var. serratum Nakai, and Aster yomena; and a second ingredient containing glycerin, caprylic or capric triglyceride, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate, PEG-4 olivate, meadowfoam seed oil, dimethicone, cetyl ethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymers, stearyl glycyrrhetinate, sodium chloride, sodium acrylate or sodium acryloyldimethyl taurate copolymers, algin, isohexadecane, caprylyl glycol, polysorbate 80, allantoin, capryl hydroxamic acid, propylene glycol, disodium EDTA, and ceramide 3. The first and second ingredients are mixed in a weight ratio of 5:5-7:3.

Description

Therapeutic Effects Cream for Anti-atopic}

The present invention relates to an anti-atopic cream having a therapeutic effect of atopic dermatitis by applying anti-atopic cream in DNCB-induced atopic dermatitis mice, while lowering blood IgE and inhibiting the release of histamine produced in mast cells.

The present invention relates to an anti-atopic cream having a therapeutic effect of atopic dermatitis by applying anti-atopic cream in DNCB-induced atopic dermatitis mice, while lowering blood IgE and inhibiting the release of histamine produced in mast cells.

Recently, the number of children and adolescent atopic dermatitis has increased rapidly in Korea.

According to the 2008 National Health and Nutrition Survey, atopic dermatitis was reported in 19.2% of children between the ages of 1 and 5, with 1 in 5 people suffering from it (NHNS, 2009).

Atopic dermatitis is a chronic inflammatory skin disease that is characterized by itching and inflammation. When allergens, which are allergic agents of atopic dermatitis, enter the body from the outside, IgE is produced in blood B-cells, and the mast cells of the skin. It is known that allergens are caused by histamine being released when it is repeatedly exposed to the allergen after generating and storing histamine by binding to basophils, which are white blood cells.

The cause of atopic dermatitis is not clear, but it is known to be caused by a combination of genetic predisposition, immunological factors, and environmental factors.

The treatment of itching associated with scratching is thought to be an effective treatment for atopic dermatitis.

Antihistamine treatment is not sufficient to suppress itching in patients with atopic dermatitis and steroid application is not available in the long term because of frequent side effects (Jiang et al., 2009; Yun et al., 2008; Koblenzer, 1999; Mihara et al. , 2004).
Background art of the present invention is Korean Patent Publication No. 10-2013-0030491 published on March 27, 2013 "Pharmaceutical composition for treating atopy and acne" and Republic of Korea Patent Publication published on June 7, 2012 10-2012-0058202 "vegetable antimicrobial compositions and cosmetic compositions for skin improvement using the same" is disclosed.

An object of the present invention devised to solve the above problems, the treatment of atopic dermatitis by applying anti-atopic cream in DNCB-induced atopic dermatitis mice by lowering blood IgE and inhibiting the emission of histamine produced in mast cells It is to provide an anti-atopic cream having an effect.

The purpose of this study was to investigate the anti-atopic efficacy evaluation of DNCB-induced BALB / c atopic dermatitis mice in order to investigate the atopic dermatitis treatment effect of NJY Life Science.

Twenty male BALB / c mice were used for the atopic dermatitis induction control group and the anti-atopic cream treatment group.

When atopic dermatitis was applied to the mice with severe atopic dermatitis, it was observed that the anti-topic dermatitis was applied twice a day for 6 days to restore normal skin condition and to a clean and smooth state without dead skin cells. Blood IgE and histamine concentrations showed a significant decrease of 57.80% and 59.41% dml, respectively, in the anti-atopic cream treatment group compared to the DNCB-induced atopy control (p <0.05). Compared with the severe atopic dermatitis, mice treated with anti-atopic dermatitis had a uniform surface thickness of the epidermal layer, a smooth surface layer, and a connective tissue formed in a more uniform direction.

According to a feature of the present invention for achieving the above object, the present invention, the first component, including Eoseongcho, Seokchangpo, Windproof, Astragalus, Bifa leaf, Gosam, Triticales, Hwangbaek, Centella, Cheonnamseong and Mugwort; And glycerin, caprylic or capric triglycerides, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate, sebum- 4 oleate, meadowfoam seed oil, dimethicone, cetylethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, stearyl glycyrrheti Nate, Sodium Chloride, Sodium Acrylate or Sodium Acryloyl Dimethyl Taurate Copolymer, Algin, Isohexadecane, Caprylyl Glycol, Polysorbate 80, Allantoin, Capryl Hydroxamic Acid, Propylene Glycol, A second component comprising disodium ethane and ceramide 3; wherein the first component and the second component are in a weight ratio of 5: 5 to 7: 3 Characterized in that the washing.

In addition, the first component is 55 to 65 parts by weight of purified water, 7 to 9 parts by weight of the extract of fish vinegar, 4 to 6 parts by weight of the root or stem extract of stone spear, 3 to 5 parts by weight of wind extract, 2 to 4 parts by weight of Astragalus extract , 5 to 7 parts by weight of loquat leaf extract, 2 to 4 parts by weight of red ginseng extract, 4 to 6 parts by weight of Sambaekcho extract, 3 to 5 parts by weight of yellow white extract, 1 to 3 parts by weight of Centella extract, 0.5 to 1.5 parts by weight of Chonnam extract And mugwort extract is characterized in that it comprises 0.5 to 1.5 parts by weight.

In addition, the second component is glycerin, caprylic or capric triglyceride 8 to 10 parts by weight, sunflower seed oil 4 to 6 parts by weight, butylene glycol 3 to 5 parts by weight, butylene glycol dicaprylate Or 3 to 5 parts by weight of dicaprate, 1 to 3 parts by weight of macadamia seed oil, 0.5 to 1.5 parts by weight of polyglyceryl-3 methylglucose distearate, 0.5 to 1.5 parts by weight of sebum-4 olivate, meadowfoam seed oil 0.5 to 1.5 parts by weight, dimethicone 0.5 to 1.5 parts by weight, cetylethylhexanoate 0.5 to 1.5 parts by weight, oxidized corn oil 0.4 to 1.4 parts by weight, cetearyl alcohol 0.3 to 1.3 parts by weight, tocopheryl 0.3 to 0.7 parts by weight of acetate, 0.3 to 0.7 parts by weight of glyceryl acrylate or acrylic acid copolymer, 0.3 to 0.7 parts by weight of stearyl glycyrrhetinate, 0.3 to 0.7 parts by weight of sodium chloride, 0.3 to 0.7 parts by weight of sodium acrylate or sodium acryloyl dimethyl taurate copolymer, 0.3 to 0.7 parts by weight of algin, 0.2 to 0.4 parts by weight of isohexadecane, 0.2 to 0.4 parts by weight of caprylyl glycol, polysorbate 80 0.1 to 0.3 parts by weight, allantoin 0.1 parts by weight, capryl hydroxamic acid 0.1 parts by weight, propylene glycol 0.1 parts by weight, 0.05 parts by weight of disodium ethane and 0.05 parts by weight of ceramide3.

According to the present invention as described above, applying anti-atopic cream in DNCB-induced atopic dermatitis mice anti-atopic cream having a therapeutic effect of atopic dermatitis by lowering blood IgE and inhibiting the release of histamine produced in mast cells Can be provided.

1A to 1D are photographs showing the therapeutic effect of anti-atopic cream in atopic dermatitis mice induced by DNCB according to a preferred embodiment of the present invention.
2A to 2C are photographs showing skin microscopic comparisons of the effects of anti-atopic creams in atopic dermatitis mice induced by DNCB according to a preferred embodiment of the present invention.

green

The purpose of this study was to investigate the anti-atopic efficacy evaluation of DNCB-induced BALB / c atopic dermatitis mice in order to investigate the atopic dermatitis treatment effect of NJY Life Science.

Twenty male BALB / c mice were used for the atopic dermatitis induction control group and the anti-atopic cream treatment group.

When atopic dermatitis was applied to the mice with severe atopic dermatitis, it was observed that the anti-topic dermatitis was applied twice a day for 6 days to restore normal skin condition and to a clean and smooth state without dead skin cells. Blood IgE and histamine concentrations showed a significant decrease of 57.80% and 59.41% dml, respectively, in the anti-atopic cream treatment group compared to the DNCB-induced atopy control (p <0.05). Compared with the severe atopic dermatitis, mice treated with anti-atopic dermatitis had a uniform surface thickness of the epidermal layer, a smooth surface layer, and a connective tissue formed in a more uniform direction.

Introduction

Recently, the number of children and adolescent atopic dermatitis has increased rapidly in Korea.

According to the 2008 National Health and Nutrition Survey, atopic dermatitis was reported in 19.2% of children between the ages of 1 and 5, with 1 in 5 people suffering from it (NHNS, 2009).

Atopic dermatitis is a chronic inflammatory skin disease that is characterized by itching and inflammation. When allergens, which are allergic agents of atopic dermatitis, enter the body from the outside, IgE is produced in blood B-cells, and the mast cells of the skin. It is known that allergens are caused by histamine being released when it is repeatedly exposed to the allergen after generating and storing histamine by binding to basophils, which are white blood cells.

The cause of atopic dermatitis is not clear, but it is known to be caused by a combination of genetic predisposition, immunological factors, and environmental factors.

The treatment of itching associated with scratching is thought to be an effective treatment for atopic dermatitis.

Antihistamine treatment is not sufficient to suppress itching in patients with atopic dermatitis and steroid application is not available in the long term because of frequent side effects (Jiang et al., 2009; Yun et al., 2008; Koblenzer, 1999; Mihara et al. , 2004).

Research is underway to develop anti-atopic materials from natural products, and anti-atopic efficacy has been reported in golden hydrothermal extracts, tofu extracts, millennial extracts, kimchi extracts, and non-leaflets and triticale extracts (Kwon et al., 011; Choi et al. , 2010; Lee et al., 2008; Shon and Nam, 2007; Kim et al., 2007; Kim and Park, 2006).

Traditionally, Houttuynia cordata, Arorus gramineus Soland, Windproof (Saposhnikivia divaricata Schisck), Astragalus membranaceus, Loquat (Eriobotrya japonica L), Sophora flavescens Ait. It is known to have various pharmacological effects including anti-inflammatory in plants.

Quercetin of Seongcho, Asarone of Sukchangpo, Coumarin of Windproof, Formononetin of Astragaloside, Astragaloside of Astragalus, Terpenoid, Amygdalin, Saponin, Quercetin of 300 seconds, Flavonoid of Red Ginseng are known as major pharmacological ingredients (Jung and Cho, 2010) ; Ferreres et al., 2009; Jeong et al., 2009; Kwon and Shin 2009; Kim et al., 2005; Ro et al., 1998) NJY Life Sciences mixed these plant extracts to produce anti-atopic creams. .

This study investigated the anti-atopic efficacy evaluation of DNCB-induced BALB / c mice to investigate the atopic dermatitis treatment effect of anti-atopic creams provided by NHY Life Sciences.

Materials and methods

Experimental material

The anti-atopic cream was supplied by NJY Life Science Co., Ltd. The anti-atopic cream consists of the first ingredient and the second ingredient.

The first component includes Eoseongcho, Seokchangpo, Windproof, Astragalus, Loquat Leaf, Gosam, Sanbaekcho, Hwangbaek, Centella, Cheonnamseong and Mugwort.

Here, the first component is 55 to 65 parts by weight of purified water, 7 to 9 parts by weight of fish extract, 4 to 6 parts by weight of root or stem extract of Seokchangpo, windproof extracts 3 to 5 parts by weight, Astragalus extract 2 to 4 parts by weight, Loquat leaf extract 5 to 7 parts by weight, red ginseng extract 2 to 4 parts by weight, Sambaekcho extract 4 to 6 parts by weight, yellow white extract 3 to 5 parts by weight, Centella extract 1 to 3 parts by weight, Chonnam extract 0.5 to 1.5 parts by weight and Mugwort berry extract contains 0.5 to 1.5 parts by weight.

The second component is glycerin, caprylic or capric triglycerides, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate , PIG-4 oleate, meadowfoam seed oil, dimethicone, cetylethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, ste Arylglycitinate, sodium chloride, sodium acrylate or sodium acryloyl dimethyl taurate copolymer, algin, isohexadecane, caprylglycol, polysorbate 80, allantoin, caprylhydroxamic acid, propylene Glycols, disodium etieti and ceramide 3.

Here, the second component is 20 to 25 parts by weight of glycerin, 10 to 15 parts by weight of caprylic or capric triglycerides, 10 to 15 parts by weight of sunflower seed oil, 7 to 12 parts by weight of butylene glycol, butylene glycol 7 to 12 parts by weight of cold dicaprylate or dicaprate, 2 to 7 parts by weight of macadamia seed oil, 1.5 to 3.5 parts by weight of polyglyceryl-3 methylglucose distearate, 1.5 to 3.5 parts by weight of Fiji-4 olivate, Meadowfoam seed oil 1.5 to 3.5 parts by weight, dimethicone 1.5 to 3.5 parts by weight, cetylethylhexanoate 1.5 to 3.5 parts by weight, oxidized corn oil 1.4 to 3.4 parts by weight, cetearyl alcohol 0.7 to 2.3 parts by weight Part, 0.7 to 1.5 parts by weight of tocopheryl acetate, 0.7 to 1.5 parts by weight of glyceryl acrylate or acrylic acid copolymer, 0.7 to 1.5 parts by weight of stearyl glycyretinate, sodium chloride 0.7 to 1.5 parts by weight, sodium acrylate or sodium acryloyl dimethyl taurate copolymer 0.7 to 1.5 parts by weight, algin 0.7 to 1.5 parts by weight, isohexadecane 0.6 to 1.2 parts by weight, caprylyl glycol 0.6 to 1.0 weight Parts, 0.2 to 0.6 parts by weight of polysorbate 80, 0.25 parts by weight of allantoin, 0.25 parts by weight of caprylhydroxamic acid, 0.25 parts by weight of propylene glycol, 0.17 parts by weight of disodium ethane, and 0.17 parts by weight of ceramide 3 do.

In addition, the first component and the second component are mixed in a weight ratio of 5: 5 to 7: 3.

In addition, the anti-atopy cream is nano-crushed by drying the first component prepared in a liquid form, and mixing the first component, which is milled in a nano-size, with a second component composed of a liquid form in a weight ratio of 5: 5 to 7: 3. To be manufactured.

In addition, the tofu of Chunnam Root of the first component contains toxic alkaloids, and the roots, leaves, and stems contain strong toxins, soaked in white rice for one month, and then boiled in ginger juice to remove the toxicity. It is preferable.

Here, since the nano-crusher for nano-crushing the dried first component is already known technology, a detailed description thereof is omitted.

Experimental animal

All scientific procedures, including animals, followed the criteria set out in the European Laboratory Animal Handling License (SCT-w94058) and were approved with the Kangwon National University Institutional Review Board.

Twenty five-week-old male BALB / c mice of special pathogen-free animals were purchased from Daehan Biolink Co., Ltd. and bred in a commercial pellet diet for one week.

Experimental treatment was divided into atopic dermatitis-induced control group and anti-atopic cream treatment group, which was completely randomized, and 10 animals were repeatedly used in each treatment group.

Experimental animal breeding room temperature was maintained at 20 ± 2 ℃ relative humidity 60 ± 5% and the illumination was adjusted in a 12 hour cycle.

In particular, the day cycle was darkened (09: 00 ~ 21: 00) in order to minimize the stress of rats according to the experimental procedure, considering the physiological characteristics of the nocturnal rats.

The experimental diet was pelletized after preparing a tablet diet based on AIN-76.

The dietary composition consists of 20.0% casein, corn starch 15.0%, sugar 50.0%, a-cellulose 5.0%, corn oil 5.0%, mineral mixture 3.5%, vitamin mixture 1.0% Choline bitrartrate 0.2%, DL-methionine 0.3% And energy and protein content in the diet were equally controlled.

Experimental feed and water were unlimitedly supplied, and other specification management was carried out by the Kangwon National University method.

Dermatitis induction and sample processing

The back of BALB / c mice was dehydrated and left for 24 hours to heal fine wounds on the skin.

Induced immunization reaction by applying 200uL of 2.5% DNCB solution (2,4-Dinitrochloro benzene, Sigm, St. Louis, MO, USA) as an immuno-disrupting substance prepared by mixing 3: 1 of acetone and olive oil. It was.

Atopy dermatitis was induced by applying 150 uL of 1.0% DNCB solution once every 3 days to 3 days after 3 days.

After applying the DNCB solution to the back twice, the scalding was intensified, and the skin on the back began to peel off, causing atopic dermatitis.

After four application, atopic dermatitis was seriously induced. From this time, anti-atopic cream was applied to the site of inflammation.

Anti-atopic cream was applied twice a day (11:00, 17:00).

In order to prevent an error caused by natural healing during the application of anti-atopic cream, 150 μL of 1.0% DNCB solution was applied to the back of the mouse once every three days (10:00).

Blood and skin tissue collection

At the end of the experiment, mice were lightly anesthetized with ethyl ether, 1.0 ml of blood was collected from the heart using an SST tube (Serum Separate Tube), and left to stand at room temperature for 20 minutes to allow blood to coagulate.

Serum was separated from the coagulated blood by centrifugation at 3,000 rpm for 10 minutes and rapidly frozen in liquid nitrogen at −196 ° C. and then frozen at −20 ° C.

Immediately, the mice were euthanized by the cervical vertebra and skin tissues were collected by cutting back skin tissue into 1 × 2 cm 2.

blood IgE Measure

Immunoglobulin E concentration from blood was calculated by using Mouse IgE ELISA Kit (Shibayagi Co., Ltd, Gunma, Japan) as follows and comparing the absorbance of the standard solution.

The well plate and all reagents were kept at room temperature and the concentrated wash solution diluted 10-fold with distilled water.

IgE standard concentrations (0, 1.0, 10, 25, 50, 75, 100 ng-mL) were prepared using IgE standards and buffer solutions, respectively.

Antibody-coated plates were washed three times by filling 96 wells with the wash solution.

The plate was shaken slowly on a plate shaker (800 rpm for 10 seconds x 3 times) by dispensing 50 uL of diluted sample and standard solution.

After incubating for 2 hours at room temperature, the reaction mixture was discarded.

After washing three times with the washing solution, 50 uL of Biotin-Conjugated anti-IgE antibody was dispensed into all wells and shaken by the procedure described above.

After incubation at room temperature for 2 hours, the reaction mixture was discarded and treated in the same manner as the previous procedure.

After dispensing 50 uL of HRP-Conjugated avidin, the plate was shaken in the same manner as before, and the plate was incubated at room temperature for 1 hour.

After the reaction mixture was discarded and washed three times, 50uL of Chromogenic substrate reagent was added thereto, shaken in the same manner as the previous procedure, and the plate was incubated at room temperature for 20 minutes.

After adding 50 uL of reaction stopper to all wells, it was shaken as described above.

Within 30 minutes, the absorbance of each well was measured by a Microplate Reader (Molecular Devices Inc, New York, USA).

IgE measurements were performed in duplicate.

Blood histamine measurement

Histamine in blood was measured using a mouse histamine ELISA kit (IBL-America, Inc., Minneapolis, MN, USA) as follows.

100 uL of serum was added to an acylation tube, and 50 uL of acylation buffer was added thereto, followed by reaction for 30 minutes at 18 ° C. 50 uL of acylated plasma was added to 96 wells containing histamine antibody, and 200 uL of enzyme conjugate was added thereto, followed by incubation at 4 ° C. for 18 hours.

The contents of the test wells were aspirated and washed three times with the washing solution, and 200 uL of chromogenic substrate reagent was added to the wells for 20 minutes at room temperature.

Histamine concentration was calculated by measuring the absorbance at 450 nm using a microplate plate reader (Molecular Devices Inc, New York, USA).

The histamine was measured in a double repetition, and the standard solution was performed in the same manner as above, and then the absorbance of the samples was compared.

Observation method of skin tissue cells

The skin tissue of the mouse was biopsied at a width of 1.5 × 1.5 cm 2 around the affected area around the back, fixed in 10% formaldehyde solution, and stored at 4 ° C. until immediately before tissue staining.

The sample was fixed with 4% glutaraldehyde solution (0.1M cacodylate buffer, pH 7.4), followed by dehydration, substitution, infiltration and embeddingm polymerization, semi-tjin sectioning, and energy filtration electron microscopy (EF-TEM, Leo 92AB, Carl). Zeiss Inc., Germany).

Skin tissues were observed mainly on the overall condition of the skin, infiltration and degranulation of mast cells, and eosinophil infiltration.

Statistical processing

Statistical analysis of the analyzed data was carried out using SAS program, and the average and standard error of each treatment group were calculated, variance analysis was performed, and the significance was tested at the 95% level by Duncan's multiple range test (SAS, 2000).

Results and Discussion

Visual observation

Figure 1 shows the appearance of atopic dermatitis mice produced by DMNCB induction. After depilation of the mouse (Fig. 1a), the application of DNCB solution forms a crust (Fig. 1b), which causes severe itching of the mouse that is difficult to tolerate itching and the peeling of the skin. It can be seen that dermatitis progressed and atopic dermatitis was caused to a serious condition (FIG. 1C). Mice with severe atopic dermatitis developed skin damage such as erythema, wound erosion, hair loss, dry skin, bleeding and inflammation when compared with the anti-atopic cream treatment group. In this condition, anti-atopic dermatitis applied twice a day for 3 days, the dermatitis of the affected area improved drastically, and applied for 6 days to almost normal skin condition, and to a clean and smooth state with no dead skin cells on the skin surface. It can be observed that (Fig. 1d). Itching is one of the most common symptoms of skin disease and can be caused by inflammation, cancer, metabolic diseases, infections, mental illness, medications, stress and other factors, and activation of mast cells worsens atopic dermatitis in humans (Elenkov, 2008; Paus et al., 2006 Stander et al., 2003). The fact that anti-atopic dermatitis was applied to atopic dermatitis mice showed a decrease in blood IgE and histamine release (Table 1).

Effect of Anti-Atopy Cream on Serum IgE and Histamine Concentrations in DBLBB-induced Atopic Dermatitis Mice BALB / c (ng / mL) division Atopy control Anti Atopic Cream Treatment Group IgE 56.28 ± 5.36 23.75 ± 2.48 Histamine 40.08 ± 3.51 16.27 ± 4.12

Mean ± standard error (observation = 10). * Significantly different at the 95% confidence level (p <0.05).

In the blood IgE  And histamine concentration changes

The blood IgE concentration was measured to decrease 32.53 ng per mL in the anti-atopic cream treatment group compared to the DNCB-induced atopy control group with a significant decrease of 57.80% (p <0.05).

The blood histamine concentration was measured to decrease 23.81 ng per mL in the anti-atopic cream treated group compared to the DNCB-induced atopy control group and showed a significant decrease rate (p <0.05) of 59.41% (Table 1).

The above results suggest that the application of anti-atopic cream to atopic dermatitis mice has a therapeutic effect of atopic dermatitis by lowering the production of blood IgE and inhibiting the release of histamine (FIG. 1).

Increasing IgE levels in serum is known as an immunological indicator of atopic dermatitis. In particular, IgE is known to be proportional to clinical severity in atopic dermatitis patients.

IgE has been reported to produce histamine in combination with leukocytes of skin mast cells and to cause allergic reactions by reacting with invasive antigens (Sung et al., 2006; Latvala, 2005; Ban and Hetich, 2001; Matsuda et al., 1997; Metcalfe et al., 1981).

Skin allergic reactions cause vasodilation, capillary permeability, increased mucus, and swelling and inflammation of the mucous membranes by various compounds caused by the chemical transporter histamine or T lymphocytes that the immunoglobulin IgE reacts with and releases to the antigen. Church and Levi-Schaffer. 1997; Ishizaka, 1984).

In atopic dermatitis, histamine is a major cause of pruritus, and it has been reported that histamine is increased in atopic patients compared to normal people.

The skin has the opportunity to contact numerous antigens, forming a boundary between the external environment and the body.

When atopic dermatitis develops, the skin is irritated and the threshold for pruritus decreases, and the stimulation and inflammatory reactions of the skin secrete cytokines from the keratinocytes of the skin, which intensify the inflammatory response and induce deformation of the stratum corneum. Activate the cell.

Activation of immune cells leads to increased IgE production and increased antibody response and increased histamine secretion by increasing the activity of IgE dependent histamine vitreous.

Histamine induces eosinophil infiltration and causes acute hypersensitivity and pruritus (Budde et al., 2002; White, 1990; Ennis et al., 1980).

Histopathological Findings

As a result of observing the skin surface after applying anti-atopic cream, the surface thickness of the epidermal layer was uniform and the surface layer was formed smoothly and the connective tissue was formed in a more uniform direction compared with the treatment group of atopic dermatitis induced by DNCB (Fig. 2b). It was confirmed that the recovery similar to the normal group (Fig. 2a) (Fig. 2c).

In the case of the dermal layer treated with anti-atopic dermatitis, atopic dermatitis induced by DNCB can be seen to be more active remodeling of hair follicles and sebaceous glands than in the severe treatment group.

The regeneration of skin epithelial tissue, the formation of stratum corneum, the proliferation of reticular layer and the formation of appendages in the basal layer were clearly activated.

In the anti-atopic cream treatment group, the skin surface was clean and smooth, but histologically, the skin tissue in the anti-atopic cream treatment group was significantly thicker than the epidermis of atopic dermatitis mice due to the prominent bleeding and enlargement of the epidermis. (FIG. 2C).

In contrast, the skin surface of the atopic dermatitis mouse group was very rough due to numerous keratin and local edema was confirmed.

In the epidermis of atopic dermatitis mice, the disappearance of basal layer cells was prominent, and cells related to inflammation such as lymphocytes, mast cells, neutrophils and eosinophilic leukocytes were observed in the epidermis and dermis (FIG. 2b).

However, in the treatment group coated with anti-atopic cream, these cells were hardly seen and the thickness of the epidermal layer was gradually recovered to the thickness similar to that of the normal control group (FIG. 2C).

In the skin tissue of allergic contact dermatitis, mast cells and eosinophils in which degranulation occurs are infiltrated into the skin tissue and epidermal hyperkeratosis occurs (Sator et al., 2003; Budde et al., 2002; Vestergaard et al., 1999). .

Allergic contact dermatitis is induced and water evaporation on the skin surface is increased to facilitate the penetration of antigens, which further intensifies the skin's hypersensitivity reactions, weakening the skin barrier formed by matrix structural proteins that bind to ceramides. It is known that the sensitivity is increased.

Therefore, it is best to remove irritating antigens for the treatment of dermatitis by immune response, but since specific antigens are often unknown, antibiotics and topical steroids are generally used for long-term use. Many problems have been reported in terms of stability (Stander et al., 2003).

conclusion

These results suggest that anti-atopic dermatitis treatment in DNCB-induced atopic dermatitis mice has a therapeutic effect on atopic dermatitis by lowering blood IgE and suppressing histamine release from mast cells. .

Claims (3)

First components including Eoseongcho, Seokchangpo, Windproof, Astragalus, Loquat leaf, Red ginseng, Sanbaekcho, Hwangbaek, Centella, Cheonnam and Mugwort; And
Glycerin, Caprylic or Capric Triglyceride, Sunflower Seed Oil, Butylene Glycol, Butylene Glycol Dicaprylate or Dicaprate, Macadamia Seed Oil, Polyglyceryl-3 Methyl Glucose Distearate, Fiji-4 Olibate, meadowfoam seed oil, dimethicone, cetylethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, stearyl glycyrate , Sodium chloride, sodium acrylate or sodium acryloyl dimethyl taurate copolymer, algin, isohexadecane, caprylyl glycol, polysorbate 80, allantoin, caprylhydroxamic acid, propylene glycol, di It includes; a second component comprising sodium idieti and ceramide 3,
The first component and the second component is an anti-atopic cream, characterized in that mixing at a weight ratio of 5: 5 to 7: 3.
The method of claim 1, wherein the first component,
55 to 65 parts by weight of purified water, 7 to 9 parts by weight of eochochocho extract, 4 to 6 parts by weight of root or stem extract of Seokchangpo, windproof extracts 3 to 5 parts by weight, 2 to 4 parts by weight of Astragalus extract, 5 to 7 loquat leaf extract Parts by weight, red ginseng extract 2 to 4 parts by weight, sambaekcho extract 4 to 6 parts by weight, yellow white extract 3 to 5 parts by weight, centellar extract 0.5 to 1.5 parts by weight, Chonnam extract 0.5 to 1.5 parts and mugwort berry extract 0.5 to 1.5 parts by weight Anti-atopic cream comprising a part.
The method of claim 1, wherein the second component,
20 to 25 parts by weight of glycerin, 10 to 15 parts by weight of caprylic or capric triglycerides, 10 to 15 parts by weight of sunflower seed oil, 7 to 12 parts by weight of butylene glycol, butylene glycol dicaprylate or dicaprate 7 to 12 parts by weight, 2 to 7 parts by weight of macadamia seed oil, 1.5 to 3.5 parts by weight of polyglyceryl-3 methylglucose distearate, 1.5 to 3.5 parts by weight of sebum-4 olivate, and 1.5 to 3.5 parts of meadowfoam seed oil Parts by weight, dimethicone 1.5 to 3.5 parts by weight, cetylethylhexanoate 1.5 to 3.5 parts by weight, oxidized corn oil 1.4 to 3.4 parts by weight, cetearyl alcohol 0.7 to 2.3 parts by weight, tocopheryl acetate 0.7 to 1.5 parts by weight, glyceryl acrylate or acrylic acid copolymer 0.7 to 1.5 parts by weight, stearyl glycyretinate 0.7 to 1.5 parts by weight, sodium chloride 0.7 to 1.5 parts by weight, 0.7 to 1.5 parts by weight of sodium acrylate or sodium acryloyl dimethyl taurate copolymer, 0.7 to 1.5 parts by weight of algin, 0.6 to 1.2 parts by weight of isohexadecane, 0.6 to 1.0 parts by weight of caprylyl glycol, polysorbate 80 0.2 to 0.6 parts by weight, allantoin 0.25 parts by weight, capryl hydroxamic acid 0.25 parts by weight, propylene glycol 0.25 parts by weight, disodium idieti 0.17 parts and ceramide 3 comprising 0.17 parts by weight Atopy cream.

Images